Skip to main content
CYCLOPHARM LIMITED logo

CYCLOPHARM LIMITED — Investor Relations & Filings

Ticker · CYC ISIN · AU000000CYC5 LEI · 9845008C9R4608FB7007 ASX Manufacturing
Open in API
Filings indexed 777 across all filing types
Latest filing 2016-02-23 Annual Report
Country AU Australia
Listing ASX CYC

About CYCLOPHARM LIMITED

https://www.cyclopharm.com.au

Cyclopharm Limited focuses on the development and commercialization of specialized medical imaging technologies. Its primary product, Technegas, is an ultra-fine dispersion of carbon nano-particles labeled with Technetium-99m, utilized for functional lung ventilation imaging. This technology is used to diagnose Pulmonary Embolism by providing high-resolution images via the inhalation of a radioactive aerosol. Technegas is generated on-site using proprietary equipment and is compatible with SPECT and SPECT/CT imaging. The system is engineered to provide diagnostic clarity even in patients with underlying airway diseases. Beyond its primary diagnostic use, the company investigates applications for its technology in managing chronic obstructive pulmonary disease (COPD), asthma, and lung cancer.

Recent filings

Filing Released Lang Actions
Preliminary Final Report 63 pages 1.1MB
Annual Report Classification · 95% confidence The document is titled 'Cyclopharm Limited Appendix 4E' and contains detailed financial results for the year ended 31 December 2015, including revenues, profits, dividends, and operational highlights. It includes a Managing Director's Report and commentary on the full year results, with extensive financial data and analysis. The document references audited accounts in process and provides comprehensive financial performance metrics, cash flow, and segment results. Appendix 4E is a known Australian regulatory filing format for preliminary final reports, which are essentially annual financial reports. The document is lengthy (15,000 characters) and contains substantive financial data and management discussion, indicating it is the actual report rather than an announcement of a report. Therefore, this document fits the definition of an Annual Report (10-K equivalent). FY 2015
2016-02-23 English
Strong Technegas Earnings Underpin Record Profit 3 pages 96.5KB
Annual Report Classification · 95% confidence The document is a detailed announcement from Cyclopharm Limited reporting its financial results for the year ended 31 December 2015. It includes comprehensive financial data such as net profit, sales revenue, EBITDA, cash flow, earnings per share, and dividend declarations. The document also discusses operational achievements, product updates, and outlook for the company. The presence of full-year financial figures, discussion of profit and loss, cash flow, and dividends indicates this is a full annual financial report rather than a brief earnings release or dividend notice. The length of the document (8483 characters) and the detailed financial and operational information confirm it is not merely an announcement of a report but the report itself. Therefore, the document fits the definition of an Annual Report (10-K equivalent). FY 2015
2016-02-23 English
Dividend/Distribution - CYC 3 pages 26.5KB
Notice of Dividend Amount Classification · 100% confidence The document is a notification of dividend/distribution for Cyclopharm Limited, detailing the dividend amount, ex-date, record date, and payment date. It provides specific dividend payment information but does not contain comprehensive financial statements or analysis. The document is an announcement of dividend details rather than a full financial report or management discussion. Therefore, it fits the category of Notice of Dividend Amount (DIV). The document length is 4155 characters, which is consistent with a detailed dividend announcement but not a full report.
2016-02-23 English
Technegas COPD Trial Update 2 pages 290.0KB
Regulatory Filings Classification · 95% confidence The document is a company announcement from Cyclopharm Limited dated 29 January 2015, reporting preliminary results from clinical trials of their Technegas product in China for diagnosing and managing Chronic Obstructive Pulmonary Disease (COPD). The text includes background information about the company and its products, market potential, and trial details. It is a news release style document aimed at informing the market and investors about trial progress and potential growth opportunities. There are no financial statements, detailed financial analysis, or regulatory filings such as annual or interim reports. The document is not a transcript, audit report, or management discussion. It is a corporate announcement about clinical trial results and business prospects, which fits best under Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2016-01-28 English
Cyclopharm receives insurance settlement 2 pages 209.7KB
Regulatory Filings Classification · 95% confidence The document is a short announcement from Cyclopharm Ltd dated 31 December 2015, informing shareholders about an insurance settlement related to water damage at a facility. It mentions the settlement amount and that the funds will be reflected in the 2015 full year accounts. The document also provides background information about the company and its products. There are no financial statements, detailed financial analysis, or comprehensive report content. The length is only 3121 characters, which is quite short and more consistent with an announcement rather than a full report. The document does not present itself as a full Annual Report or Interim Report but rather as a company announcement regarding a specific event (insurance settlement). Therefore, it fits best as a Regulatory Filing (RNS), which is the fallback category for miscellaneous announcements that do not fit other specific categories.
2015-12-30 English
Change of Director's Interest Notice 2 pages 141.5KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details a director's disposal of shares, including the number of securities held before and after the change, the nature of the change (on-market trade), and other related information. This is a report of personal share transactions by a company director, which fits the definition of 'Director's Dealing'. The document length is 3274 characters, which is consistent with a detailed notice rather than a brief announcement. Therefore, the appropriate classification is DIRS (Director's Dealing).
2015-11-25 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.